Drug Approval | November 10, 2025
Johnson & Johnson gets FDA nod for new depression treatment
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
While the trial fell short of demonstrating a statistically significant PFS benefit compared to chemotherapy, early data suggest a potential overall survival advantage
The pharma giant's 11% rise in total revenue to $43.2 billion highlights consistent execution of its growth strategy
The upcoming facility marks a strategic milestone in SOUKYA’s mission to make evidence-based holistic healthcare
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
The offering is expected to close on November 10, 2025, subject to customary closing conditions
Venus Remedies now has 29 active product approvals in Vietnam alone
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
A bio-analytical Remote Regulatory Assessment was also conducted from October 30 to November 7, 2025, and concluded with no observations
Subscribe To Our Newsletter & Stay Updated
